Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright

HC Wainwright restated their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a $75.00 target price on the biotechnology company’s stock.

A number of other equities research analysts have also weighed in on the company. Evercore ISI reduced their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Guggenheim lifted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Robert W. Baird reduced their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Finally, Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $176.77.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $107.95 on Thursday. Sarepta Therapeutics has a one year low of $102.15 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a market cap of $10.31 billion, a price-to-earnings ratio of 86.36 and a beta of 0.75. The firm has a 50 day simple moving average of $119.42 and a 200 day simple moving average of $124.72.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the business. Capital International Investors raised its stake in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Norges Bank bought a new stake in Sarepta Therapeutics during the fourth quarter worth $126,315,000. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares during the last quarter. Erste Asset Management GmbH bought a new position in Sarepta Therapeutics during the 3rd quarter valued at $79,425,000. Finally, Janus Henderson Group PLC boosted its holdings in Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after acquiring an additional 543,143 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.